Deciphera Pharmaceuticals... (DCPH)
NASDAQ: DCPH
· Real-Time Price · USD
25.59
0.02 (0.08%)
At close: Jun 10, 2024, 10:00 PM
Deciphera Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 45M | 48.29M | 43.31M | 38.3M | 33.45M | 36.34M | 35.97M | 32.49M | 29.22M | 24.2M | 23.22M | 23.57M | 25.16M |
Cost of Revenue | 3.69M | 1.78M | 1.29M | 173K | 488K | 3.25M | 3.34M | 1.8M | 382K | 518K | 917K | 1.27M | 222K |
Gross Profit | 41.31M | 46.51M | 42.03M | 38.13M | 32.96M | 33.1M | 32.63M | 30.7M | 28.84M | 23.68M | 22.3M | 22.3M | 24.93M |
Operating Income | -48.85M | -51.24M | -53.69M | -52.77M | -53.26M | -47.16M | -44.88M | -43.79M | -47.67M | -88.4M | -79.67M | -70.51M | -61.49M |
Interest Income | 3.76M | 4.48M | 4.11M | 4.21M | 3.65M | 1.93M | 1.84M | 727K | n/a | 6K | n/a | 81K | 196K |
Pretax Income | -45.08M | -46.76M | -49.58M | -48.56M | -49.61M | -45.23M | -43.04M | -43.06M | -46.89M | -88.4M | -79.84M | -70.43M | -61.3M |
Net Income | -45.08M | -47.19M | -49.58M | -48.56M | -49.61M | -45.94M | -39.37M | -41.61M | -46.11M | -88.39M | -79.84M | -70.43M | -61.3M |
Selling & General & Admin | 32.78M | 39.15M | 33.25M | 32.61M | 31.45M | 32.2M | 30.03M | 29.63M | 28.32M | 37.15M | 35.53M | 32.83M | 30.75M |
Research & Development | 57.38M | 58.6M | 62.46M | 58.3M | 54.77M | 48.07M | 47.48M | 44.86M | 47.41M | 74.93M | 66.44M | 59.98M | 55.68M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 90.16M | 97.75M | 95.72M | 90.91M | 86.21M | 80.26M | 77.51M | 74.48M | 75.73M | 112.08M | 101.97M | 92.81M | 86.43M |
Interest Expense | n/a | 3.65M | n/a | n/a | n/a | 1.95M | 1.84M | 727K | n/a | 6K | 170K | 81K | 196K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 93.85M | 99.53M | 97M | 91.08M | 86.7M | 83.51M | 80.86M | 76.28M | 76.11M | 112.6M | 102.89M | 94.09M | 86.65M |
Income Tax Expense | n/a | 431K | -465K | n/a | n/a | 700K | -3.68M | -1.45M | -783K | 6K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 87.39M | 86.7M | 85.79M | 85.02M | 82.68M | 76.44M | 78.21M | 71.77M | 58.62M | 58.49M | 58.11M | 57.99M | 57.75M |
Shares Outstanding (Diluted) | 87.39M | 86.7M | 85.79M | 85.02M | 82.68M | 76.44M | 78.21M | 72.13M | 58.62M | 58.49M | 58.11M | 57.99M | 57.75M |
EPS (Basic) | -0.52 | -0.54 | -0.58 | -0.57 | -0.6 | -0.6 | -0.5 | -0.58 | -0.79 | -1.51 | -1.37 | -1.21 | -1.06 |
EPS (Diluted) | -0.52 | -0.54 | -0.58 | -0.57 | -0.6 | -0.6 | -0.5 | -0.58 | -0.79 | -1.51 | -1.37 | -1.21 | -1.06 |
EBITDA | -47.25M | -50.78M | -53.69M | -52.2M | -53.26M | -47.16M | -44.14M | -42.97M | -46.89M | -88.4M | -78.91M | -69.77M | -60.76M |
EBIT | -48.85M | -43.11M | -53.69M | -52.77M | n/a | -43.27M | -41.2M | -42.33M | -47.67M | -88.4M | -79.67M | -70.35M | -61.1M |
Depreciation & Amortization | 1.6M | 456K | 465K | 571K | 608K | 601K | 742K | 820K | 783K | 780K | 759K | 743K | 732K |